A case of solitary lymph node recurrence 9 years after initial treatment for advanced premenopausal endometrioid endometrial cancer; clinical usefulness of hormonal replacement therapy.
Maaya Ono, Koji Yamanoi, Asuka Okunomiya, Yusuke Sagae, Haruko Okamoto, Masumi Sunada, Mana Taki, Masayo Ukita, Yoshitsugu Chigusa, Akihito Horie, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai
{"title":"A case of solitary lymph node recurrence 9 years after initial treatment for advanced premenopausal endometrioid endometrial cancer; clinical usefulness of hormonal replacement therapy.","authors":"Maaya Ono, Koji Yamanoi, Asuka Okunomiya, Yusuke Sagae, Haruko Okamoto, Masumi Sunada, Mana Taki, Masayo Ukita, Yoshitsugu Chigusa, Akihito Horie, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s13691-023-00599-6","DOIUrl":null,"url":null,"abstract":"<p><p>There is no consensus on the use of hormone replacement therapy (HRT) after treatment of advanced corpus cancer. We report a case of advanced corpus cancer at a young age, in which HRT was initiated 7 years after surgery, and regional lymph node recurrence was later detected. The patient was 35 years old at the time of initial treatment in X year, when she was diagnosed with stageIIIC2 corpus cancer and underwent a hysterectomy with bilateral salpingo-oophorectomy and a retroperitoneal lymphadenectomy. HRT was started at X + 7 years, and at X + 9 years, a 25 × 12-mm-sized mass was found in the hilum of the right kidney. A laparoscopic resection revealed regional lymph node recurrence of the corpus cancer. A retrospective study further revealed that a tumor measuring 12 × 3 mm was found at X + 3 years and grew to 18 × 7 mm in X + 6 years, just before the start of the HRT. We hypothesize that HRT did not induce tumor recurrence; instead, it allowed for long-term follow-up and early diagnosis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 3","pages":"168-172"},"PeriodicalIF":0.5000,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212858/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-023-00599-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
There is no consensus on the use of hormone replacement therapy (HRT) after treatment of advanced corpus cancer. We report a case of advanced corpus cancer at a young age, in which HRT was initiated 7 years after surgery, and regional lymph node recurrence was later detected. The patient was 35 years old at the time of initial treatment in X year, when she was diagnosed with stageIIIC2 corpus cancer and underwent a hysterectomy with bilateral salpingo-oophorectomy and a retroperitoneal lymphadenectomy. HRT was started at X + 7 years, and at X + 9 years, a 25 × 12-mm-sized mass was found in the hilum of the right kidney. A laparoscopic resection revealed regional lymph node recurrence of the corpus cancer. A retrospective study further revealed that a tumor measuring 12 × 3 mm was found at X + 3 years and grew to 18 × 7 mm in X + 6 years, just before the start of the HRT. We hypothesize that HRT did not induce tumor recurrence; instead, it allowed for long-term follow-up and early diagnosis.
在治疗晚期癌症后使用激素替代疗法(HRT)尚未达成共识。我们报告了一例年轻时晚期癌症体的病例,其中在手术后7年开始HRT,后来发现局部淋巴结复发。患者在X年首次治疗时35岁,诊断为II C2期癌症,并进行了子宫切除术、双侧输卵管-卵巢切除术和腹膜后淋巴结切除术。HRT在X开始 + 7年,在X + 9年,25 × 在右肾门发现12mm大小的肿块。腹腔镜切除术显示癌症体局部淋巴结复发。一项回顾性研究进一步表明 × X处发现3 mm + 3年后成长为18岁 × 7 mm in X + 6年,就在HRT开始之前。我们假设激素替代疗法不会诱发肿瘤复发;相反,它允许长期随访和早期诊断。
期刊介绍:
This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO).
- Presents an online-only collection of original case reports on all types of cancer
- In particular, welcomes molecularly analyzed cancer cases
- The Official Publication of the Japan Society of Clinical Oncology (JSCO)